CHNA VS CALA Stock Comparison

Performance

CHNA
10/100

CHNA returned -3.63% in the last 12 months. Based on SPY's performance of 12.05%, its performance is below average giving it a score of 10 of 100.

CALA
10/100

CALA returned -96.80% in the last 12 months. Based on the other stocks in it's sector with an average return of -9.81%, it's performance is below average giving it a grade of 10 of 100.

Technicals

CHNA
11/100

CHNA receives a 10 of 100 based on 14 indicators. 1 are bullish, 12 are bearish.

CALA
11/100

CALA receieves a 10 of 100 based on 14 indicators. 1 are bullish, 12 are bearish.

Volatility

CHNA
60/100

CHNA has had a higher than average amount of volatility over the last 12 months giving it a score of 60 of 100.

CALA
52/100

CALA has had a higher than average amount of volatility over the last 12 months giving it a grade of 52 of 100.

Forecast

CHNA

"Forecast" not found for CHNA

CALA
81/100

4 analysts offer 12-month price forecasts for CALA. Together, they have an average target of 2, the most optimistic forecast put CALA at 2 within 12-months and the most pessimistic has CALA at 2.

Sentiment

CHNA

"Sentiment" not found for CHNA

CALA
10/100

CALA does not have any recent conclusive social sentiment.

Earnings

CHNA

"Earnings" not found for CHNA

CALA
10/100

CALA has missed earnings 9 times in the last 20 quarters.

Profit

CHNA

"Profit" not found for CHNA

CALA
10/100

Out of the last 20 quarters, CALA has had 2 profitable quarters and has increased their profits year over year on 1 of them.

Dividend

CHNA

"Dividend" not found for CHNA

CALA
10/100

CALA has not paid a dividend in the last 5 years.

All score calculations are broken down here to help you make more informed investing decisions

Loncar China BioPharma ETF Summary

Nasdaq / CHNA

The Advisor attempts to invest all, or substantially all, of its assets in the component securities and depositary receipts that make up the index. The index seeks to track the performance of a modified equal-weighted portfolio of companies directly involved in the growth of China's pharmaceutical and biotech related industries.